Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

DREADDs: the power of the lock, the weakness of the key Favoring the pursuit of specific conditions rather than specific ligands.

Goutaudier R, Coizet V, Carcenac C, Carnicella S.

eNeuro. 2019 Sep 27. pii: ENEURO.0171-19.2019. doi: 10.1523/ENEURO.0171-19.2019. [Epub ahead of print]

2.

Long-term progression in type II spinal muscular atrophy: A retrospective observational study.

Mercuri E, Lucibello S, Pera MC, Carnicella S, Coratti G, de Sanctis R, Messina S, Mazzone E, Forcina N, Fanelli L, Norcia G, Antonaci L, Frongia AL, Pane M.

Neurology. 2019 Sep 24;93(13):e1241-e1247. doi: 10.1212/WNL.0000000000008166. Epub 2019 Aug 26.

PMID:
31451515
3.

Nigrostriatal Dopaminergic Denervation Does Not Promote Impulsive Choice in the Rat: Implication for Impulse Control Disorders in Parkinson's Disease.

Magnard R, Vachez Y, Carcenac C, Boulet S, Houeto JL, Savasta M, Belin D, Carnicella S.

Front Behav Neurosci. 2018 Dec 13;12:312. doi: 10.3389/fnbeh.2018.00312. eCollection 2018.

4.

Functional levels and MRI patterns of muscle involvement in upper limbs in Duchenne muscular dystrophy.

Brogna C, Cristiano L, Tartaglione T, Verdolotti T, Fanelli L, Ficociello L, Tasca G, Battini R, Coratti G, Forcina N, De Santis R, Norcia G, Carnicella S, Colosimo C, Carlier P, Pane M, Mercuri E.

PLoS One. 2018 Jun 20;13(6):e0199222. doi: 10.1371/journal.pone.0199222. eCollection 2018.

5.

Reversing dopaminergic sensitization.

Castrioto A, Carnicella S, Fraix V, Chabardes S, Moro E, Krack P.

Mov Disord. 2017 Dec;32(12):1679-1683. doi: 10.1002/mds.27213. Epub 2017 Nov 18. Review. No abstract available.

PMID:
29150871
6.

[Motivation and apathy in Parkinson's disease: implication of dopaminergic D3 receptors].

Favier M, Carcenac C, Savasta M, Carnicella S.

Med Sci (Paris). 2017 Oct;33(10):822-824. doi: 10.1051/medsci/20173310004. Epub 2017 Oct 10. French. No abstract available.

7.

Psychostimulant effect of dopaminergic treatment and addictions in Parkinson's disease.

Delpont B, Lhommée E, Klinger H, Schmitt E, Bichon A, Fraix V, Castrioto A, Quesada JL, Pélissier P, Kistner A, Carnicella S, Lüscher C, Broussolle E, Pollak P, Thobois S, Krack P.

Mov Disord. 2017 Nov;32(11):1566-1573. doi: 10.1002/mds.27101. Epub 2017 Jul 24.

PMID:
28737225
8.

Implication of dorsostriatal D3 receptors in motivational processes: a potential target for neuropsychiatric symptoms in Parkinson's disease.

Favier M, Carcenac C, Drui G, Vachez Y, Boulet S, Savasta M, Carnicella S.

Sci Rep. 2017 Jan 30;7:41589. doi: 10.1038/srep41589.

9.

Trait Impulsivity and Anhedonia: Two Gateways for the Development of Impulse Control Disorders in Parkinson's Disease?

Houeto JL, Magnard R, Dalley JW, Belin D, Carnicella S.

Front Psychiatry. 2016 May 30;7:91. doi: 10.3389/fpsyt.2016.00091. eCollection 2016.

10.

Emotional manifestations of PD: Neurobiological basis.

Castrioto A, Thobois S, Carnicella S, Maillet A, Krack P.

Mov Disord. 2016 Aug;31(8):1103-13. doi: 10.1002/mds.26587. Epub 2016 Apr 4. Review.

PMID:
27041545
11.

What can rodent models tell us about apathy and associated neuropsychiatric symptoms in Parkinson's disease?

Magnard R, Vachez Y, Carcenac C, Krack P, David O, Savasta M, Boulet S, Carnicella S.

Transl Psychiatry. 2016 Mar 8;6:e753. doi: 10.1038/tp.2016.17. Review.

12.

Apathy and Impulse Control Disorders: Yin & Yang of Dopamine Dependent Behaviors.

Sierra M, Carnicella S, Strafella AP, Bichon A, Lhommée E, Castrioto A, Chabardes S, Thobois S, Krack P.

J Parkinsons Dis. 2015;5(3):625-36. doi: 10.3233/JPD-150535. Review.

PMID:
25870025
13.

Subthalamic deep brain stimulation differently alters striatal dopaminergic receptor levels in rats.

Carcenac C, Favier M, Vachez Y, Lacombe E, Carnicella S, Savasta M, Boulet S.

Mov Disord. 2015 Nov;30(13):1739-49. doi: 10.1002/mds.26146. Epub 2015 Jan 14.

PMID:
25588931
14.

Implication of dopamine D3 receptor activation in the reversion of Parkinson's disease-related motivational deficits.

Carnicella S, Drui G, Boulet S, Carcenac C, Favier M, Duran T, Savasta M.

Transl Psychiatry. 2014 Jun 17;4:e401. doi: 10.1038/tp.2014.43.

15.

Intermittent ethanol access schedule in rats as a preclinical model of alcohol abuse.

Carnicella S, Ron D, Barak S.

Alcohol. 2014 May;48(3):243-52. doi: 10.1016/j.alcohol.2014.01.006. Epub 2014 Mar 15. Review.

16.

Pramipexole reverses Parkinson's disease-related motivational deficits in rats.

Favier M, Duran T, Carcenac C, Drui G, Savasta M, Carnicella S.

Mov Disord. 2014 Jun;29(7):912-20. doi: 10.1002/mds.25837. Epub 2014 Feb 11.

PMID:
24515412
17.

Loss of dopaminergic nigrostriatal neurons accounts for the motivational and affective deficits in Parkinson's disease.

Drui G, Carnicella S, Carcenac C, Favier M, Bertrand A, Boulet S, Savasta M.

Mol Psychiatry. 2014 Mar;19(3):358-67. doi: 10.1038/mp.2013.3. Epub 2013 Feb 12.

18.

The small G protein H-Ras in the mesolimbic system is a molecular gateway to alcohol-seeking and excessive drinking behaviors.

Ben Hamida S, Neasta J, Lasek AW, Kharazia V, Zou M, Carnicella S, Janak PH, Ron D.

J Neurosci. 2012 Nov 7;32(45):15849-58. doi: 10.1523/JNEUROSCI.2846-12.2012.

19.

Ethanol-mediated facilitation of AMPA receptor function in the dorsomedial striatum: implications for alcohol drinking behavior.

Wang J, Ben Hamida S, Darcq E, Zhu W, Gibb SL, Lanfranco MF, Carnicella S, Ron D.

J Neurosci. 2012 Oct 24;32(43):15124-32. doi: 10.1523/JNEUROSCI.2783-12.2012.

20.

Subthalamic stimulation in Parkinson's disease: restoring the balance of motivated behaviours.

Lhommée E, Klinger H, Thobois S, Schmitt E, Ardouin C, Bichon A, Kistner A, Fraix V, Xie J, Aya Kombo M, Chabardès S, Seigneuret E, Benabid AL, Mertens P, Polo G, Carnicella S, Quesada JL, Bosson JL, Broussolle E, Pollak P, Krack P.

Brain. 2012 May;135(Pt 5):1463-77. doi: 10.1093/brain/aws078. Epub 2012 Apr 15.

PMID:
22508959
21.

Glial cell line-derived neurotrophic factor reverses alcohol-induced allostasis of the mesolimbic dopaminergic system: implications for alcohol reward and seeking.

Barak S, Carnicella S, Yowell QV, Ron D.

J Neurosci. 2011 Jul 6;31(27):9885-94. doi: 10.1523/JNEUROSCI.1750-11.2011.

22.

AKT signaling pathway in the nucleus accumbens mediates excessive alcohol drinking behaviors.

Neasta J, Ben Hamida S, Yowell QV, Carnicella S, Ron D.

Biol Psychiatry. 2011 Sep 15;70(6):575-82. doi: 10.1016/j.biopsych.2011.03.019. Epub 2011 May 6.

23.

Role for mammalian target of rapamycin complex 1 signaling in neuroadaptations underlying alcohol-related disorders.

Neasta J, Ben Hamida S, Yowell Q, Carnicella S, Ron D.

Proc Natl Acad Sci U S A. 2010 Nov 16;107(46):20093-8. doi: 10.1073/pnas.1005554107. Epub 2010 Nov 1.

24.

Noribogaine, but not 18-MC, exhibits similar actions as ibogaine on GDNF expression and ethanol self-administration.

Carnicella S, He DY, Yowell QV, Glick SD, Ron D.

Addict Biol. 2010 Oct;15(4):424-33. doi: 10.1111/j.1369-1600.2010.00251.x.

25.

Regulation of operant oral ethanol self-administration: a dose-response curve study in rats.

Carnicella S, Yowell QV, Ron D.

Alcohol Clin Exp Res. 2011 Jan;35(1):116-25. doi: 10.1111/j.1530-0277.2010.01328.x. Epub 2010 Oct 6.

26.

Nucleus accumbens-derived glial cell line-derived neurotrophic factor is a retrograde enhancer of dopaminergic tone in the mesocorticolimbic system.

Wang J, Carnicella S, Ahmadiantehrani S, He DY, Barak S, Kharazia V, Ben Hamida S, Zapata A, Shippenberg TS, Ron D.

J Neurosci. 2010 Oct 27;30(43):14502-12. doi: 10.1523/JNEUROSCI.3909-10.2010.

27.

Long-lasting adaptations of the NR2B-containing NMDA receptors in the dorsomedial striatum play a crucial role in alcohol consumption and relapse.

Wang J, Lanfranco MF, Gibb SL, Yowell QV, Carnicella S, Ron D.

J Neurosci. 2010 Jul 28;30(30):10187-98. doi: 10.1523/JNEUROSCI.2268-10.2010.

28.

Endogenous BDNF in the dorsolateral striatum gates alcohol drinking.

Jeanblanc J, He DY, Carnicella S, Kharazia V, Janak PH, Ron D.

J Neurosci. 2009 Oct 28;29(43):13494-502. doi: 10.1523/JNEUROSCI.2243-09.2009.

29.

Prefrontal cortex and reversion of atropine-induced disruption of the degraded contingency effect by antipsychotic agents and N-desmethylclozapine in rats.

Carnicella S, Mongeot A, Bourguignon JJ, Oberling P.

Int J Neuropsychopharmacol. 2010 Feb;13(1):109-22. doi: 10.1017/S1461145709990095. Epub 2009 Jun 17.

PMID:
19531280
30.

GDNF is an endogenous negative regulator of ethanol-mediated reward and of ethanol consumption after a period of abstinence.

Carnicella S, Ahmadiantehrani S, Janak PH, Ron D.

Alcohol Clin Exp Res. 2009 Jun;33(6):1012-24. doi: 10.1111/j.1530-0277.2009.00922.x. Epub 2009 Mar 19.

31.

Cabergoline decreases alcohol drinking and seeking behaviors via glial cell line-derived neurotrophic factor.

Carnicella S, Ahmadiantehrani S, He DY, Nielsen CK, Bartlett SE, Janak PH, Ron D.

Biol Psychiatry. 2009 Jul 15;66(2):146-53. doi: 10.1016/j.biopsych.2008.12.022. Epub 2009 Feb 20.

32.

Excessive alcohol consumption is blocked by glial cell line-derived neurotrophic factor.

Carnicella S, Amamoto R, Ron D.

Alcohol. 2009 Feb;43(1):35-43. doi: 10.1016/j.alcohol.2008.12.001.

33.

GDNF--a potential target to treat addiction.

Carnicella S, Ron D.

Pharmacol Ther. 2009 Apr;122(1):9-18. doi: 10.1016/j.pharmthera.2008.12.001. Epub 2008 Dec 24. Review.

34.

GDNF is a fast-acting potent inhibitor of alcohol consumption and relapse.

Carnicella S, Kharazia V, Jeanblanc J, Janak PH, Ron D.

Proc Natl Acad Sci U S A. 2008 Jun 10;105(23):8114-9. doi: 10.1073/pnas.0711755105. Epub 2008 Jun 9.

35.

Ethanol induces long-term facilitation of NR2B-NMDA receptor activity in the dorsal striatum: implications for alcohol drinking behavior.

Wang J, Carnicella S, Phamluong K, Jeanblanc J, Ronesi JA, Chaudhri N, Janak PH, Lovinger DM, Ron D.

J Neurosci. 2007 Mar 28;27(13):3593-602.

36.

Fos immunolabelling evidence for brain regions involved in the Pavlovian degraded contingency effect and in its disruption by atropine.

Carnicella S, de Vasconcelos AP, Pain L, Majchrzak M, Oberling P.

Neuropharmacology. 2006 Jul;51(1):102-11. Epub 2006 May 6.

PMID:
16678862
37.

Cholinergic effects on fear conditioning II: nicotinic and muscarinic modulations of atropine-induced disruption of the degraded contingency effect.

Carnicella S, Pain L, Oberling P.

Psychopharmacology (Berl). 2005 Apr;178(4):533-41. Epub 2005 Feb 5.

PMID:
15696332
38.

Cholinergic effects on fear conditioning I: the degraded contingency effect is disrupted by atropine but reinstated by physostigmine.

Carnicella S, Pain L, Oberling P.

Psychopharmacology (Berl). 2005 Apr;178(4):524-32. Epub 2005 Feb 5.

PMID:
15696319

Supplemental Content

Loading ...
Support Center